Inspira Secures Vendor Approval from $12 Billion Revenue HMO (World's 2nd Largest), Enabling Immediate ART100 Deployment
MWN-AI** Summary
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) has achieved a significant milestone by securing vendor approval from Clalit Health Services, the world's second-largest Health Maintenance Organization (HMO). This approval allows the company to deploy its innovative INSPIRA™ ART100 system immediately within Clalit’s extensive medical network, which serves approximately 4.9 million members. Clalit operates 14 major hospitals, including top-rated facilities recognized for their advanced healthcare technologies.
The approval marks the transition of the ART100 from mere regulatory clearance to commercial availability, a pivotal moment that enhances Inspira’s capacity to meet the specific clinical needs in cardiopulmonary procedures within a sophisticated healthcare supply chain. This validation followed a thorough review by the Professional Committee for Medical Equipment, showcasing the ART100’s safety and efficacy—key factors for other global health systems considering similar technologies.
Dagi Ben-Noon, the CEO of Inspira Technologies, described the approval as a defining inflection point for the company, analogous to securing status with major integrated health systems like Kaiser Permanente in the U.S. He emphasized that this validation lays the groundwork for potential long-term, high-quality revenue streams and boosts the company's commercialization efforts, particularly in the U.S. and other international markets.
Inspira Technologies specializes in advanced life-support solutions, with its ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures internationally. The firm is also developing the INSPIRA ART500, which aims to facilitate oxygenation in awake patients, and the HYLA™ blood sensor platform, enhancing its position within the rapidly evolving MedTech landscape.
MWN-AI** Analysis
Inspira Technologies (NASDAQ: IINN, IINNW) recently achieved a significant milestone by receiving vendor approval from Clalit Health Services, the world's second-largest Health Maintenance Organization (HMO). This approval allows for the immediate deployment of the INSPIRA™ ART100 system, marking a pivotal moment in the company's commercial trajectory. This strategic advance provides Inspira access to Clalit’s extensive medical ecosystem, which encompasses 14 major hospitals and over 1,600 clinics serving approximately 4.9 million members.
The validation from Clalit underscores the ART100’s safety and efficacy, achieved after comprehensive technical and clinical evaluations. This endorsement is crucial for Inspira as it establishes a reference case that could facilitate further approvals and adoption in similar robust healthcare networks globally, including the U.S., where the company is eyeing significant opportunities.
Investors should view this development as a strong indicator of potential long-term, high-quality revenue streams. The scale of Clalit operations rivals leading U.S. health systems, positioning Inspira’s ART100 to become a leading solution in cardiopulmonary care. Furthermore, with Inspira’s ongoing development of next-generation systems like the ART500 and proprietary monitoring solutions such as the HYLA™ blood sensor platform, the company appears to be building a competitive edge in the MedTech landscape.
Given these factors, now may be an opportune time for investors to consider entering or increasing their position in Inspira Technologies. However, it is essential to remain cognizant of potential market risks, including regulatory hurdles and competitive pressures. A balanced approach that weighs the company's growth potential against these challenges will be vital for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
RA'ANANA, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a pivotal commercial advancement. The Company has received official approval from the Medical Equipment Committee of Clalit Health Services (“Clalit”), recognized as the second-largest integrated Health Maintenance Organization (HMO) globally. The approval enables the INSPIRA™ ART100 system for immediate procurement and operational use across Clalit's extensive medical ecosystem.
Key Highlights:
- Commercial Activation: The approval transitions the ART100 from regulatory clearance to active commercial availability within a network serving approximately 4.9 million members.
- Tier-1 Network Scale: Clalit operates 14 major hospitals (including Rabin Medical Center and Soroka Medical Center, often ranked among Newsweek's "World's Best Smart Hospitals") and over 1,600 clinics. This approval effectively opens the door to one of the most sophisticated healthcare supply chains in the world.
- Validation of Clinical Value: The approval follows a rigorous technical and clinical review by the Professional Committee for Medical Equipment regarding Thoracic and Cardiac Surgery, signaling strong validation of the ART100’s safety and efficacy profile to other global health systems.
"Securing vendor status with a health network of Clalit's magnitude, comparable in scale to leading U.S. integrated systems like Kaiser Permanente, is a definitive commercial inflection point for Inspira," stated Dagi Ben-Noon, CEO of Inspira Technologies.
"By securing this approval, we are laying the foundation for potentially long-term, high-quality revenue. This validation from a world-class, data-driven health ecosystem serves as a powerful reference case as we accelerate our commercialization efforts in the U.S. and other global markets."
The Company views this approval as confirmation of the suitability of the INSPIRA ART100 for the organization's specific clinical needs in cardiopulmonary procedures. It enables all medical centres within the Clalit network to initiate procurement processes in accordance with the organization's supply chain protocols.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.
Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses benefits and advantages of the ART100 system, the commercial potential of the ART100 system following Clalit’s approval for immediate procurement and operational use across its medical ecosystem, the validation of the ART100’s safety and efficacy profile, the belief that the Company is laying the foundation for long-term, high-quality revenue and accelerates its commercialization efforts in the U.S. and other global markets, and the suitability of the ART100 for Clalit’s specific clinical needs in cardiopulmonary procedures. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485
FAQ**
How does the approval from Clalit Health Services impact the future revenue projections for Inspira Technologies Oxy B.H.N. Ltd. IINN, particularly in terms of market penetration in both Israel and the U.S.?
What are the specific clinical needs that the INSPIRA™ ART100 system addresses for Clalit Health Services, and how does this align with the strategic vision of Inspira Technologies Oxy B.H.N. Ltd. IINN?
In what ways does the validation of the ART100’s safety and efficacy by Clalit serve as a leverage point for Inspira Technologies Oxy B.H.N. Ltd. IINN in expanding its market presence globally?
What challenges might Inspira Technologies Oxy B.H.N. Ltd. IINN face as it seeks to accelerate commercialization efforts in the U.S. and other markets post-approval from Clalit Health Services?
**MWN-AI FAQ is based on asking OpenAI questions about Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN).
NASDAQ: IINN
IINN Trading
-2.66% G/L:
$0.5771 Last:
84,223 Volume:
$0.594 Open:
